Johnson & Johnson (J&J) announced a definitive agreement whereby Cougar Biotechnology will be acquired for approximately US$1 B in a cash tender offer. Cougar’s leading product is abiraterone, a late stage, first-in-class compound for the treatment of prostate cancer.